XThis page contains elements that are not optimised for mobile viewing. Click the link below to view the page in desktop mode.
Desktop mode

Medicines under additional monitoring

Updated 23 January 2018

The concept of additional monitoring and the black symbol were implemented in the pharmacovigilance legislation which entered into force in 2012.

A medicine can become subject to additional monitoring in connection with its approval or at any time during its life cycle.

If a medicine is under additional monitoring, a black inverted triangle The black triangle This medicinal product is subject to additional monitoringis displayed in its summary of product characteristics and package leaflet with information to health professionals and patients.

See Medicines under additional monitoring for more information.

The medicines that are subject to additional monitoring are published by the European Medicines Agency (EMA) on the list of medicines under additional monitoring.

The summaries of product characteristics of medicines authorised by the Danish Medicines Agency are available at produktresume.dk.

The summaries of product characteristics of centrally authorised medicines are available at the European Medicines Agency's website.

Under Medicines authorised with a summary of the risk management plan (sRMP), you can find the sRMPs authorised in connection with national, MRP and DCP procedures.

The summaries of risk management plans (sRMPs) for centrally authorised medicines are available at the European Medicines Agency's website.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


;